

The Antibody-Drug Conjugate Community in Asia is Gearing Up for Their Annual Industry Touchpoint

15 May 2024 | News

We are less than two months away from the highly anticipated flagship meeting of the ADC community in Asia: the 3rd World ADC Asia (June 25-27, 2024 | Incheon, South Korea).



Making its triumphant return to the region this Summer, this meeting will bring together key players of the ADC landscape to discuss the most important collaborations and innovations setting trends for what's to come for the rest of the year.

The meticulously crafted 3-day agenda promises to deep dive into pressing challenges, novel payloads, unique target identification, stable linker chemistries, navigating manufacturing and regulatory hurdles, and much more, empowering you to propel ADC development and fostering innovation. [Delve into the agenda here.](#)

Prepare to interact with a distinguished lineup of over 25 industry leaders hailing from Asia, including:

1. Jinwon Jung, Senior Director, ABL Bio
2. Dohyun Nam, Chairman, Aimed Bio
3. Ziping Wei, Chief Executive Officer, Bliss Biopharma
4. Yasuyuki Kaneta, Senior Director, Daiichi Sankyo
5. Masayuki Miyano, Principal Scientist, Eisai
6. Jun Ge, Executive Director, Head of China Clinical Development, Gilead

7. Tse Wen Chang, Founder & Chairman, Immunwork
8. Sun-Hwa Lee, Chief Scientific Officer, Novelty Nobility
9. Heidi Wang, Chief Executive Officer, OBI Pharma
10. Hyun Yong Cho, Chief Scientific Officer, PinotBio

[See the full speaker faculty and session details here.](#)

Agenda Highlights

- Outlining Clinical Updates & Clinical Progression in Field to Ensure a Smooth Translation Into the Clinic
- Honing Novel Innovations in ADC Technologies Coming Out of Asia to Establish Competitive Differentiation.
- Exploring Global Manufacturing Capabilities the Challenges With Antibody Linker-Payload Supply Chain to Reduce Process Complexity Standardize ADC Development
- Identifying Novel Targets Their Benefits to Diversify ADC Programs Design a More Accurate ADC
- Innovating Novel Linker & Payload Technologies to Increase Stability, Efficiency Patient Treatability
- Maximizing Therapeutic Window to Increase Efficacy Reduce Off-Target Toxicity of ADC

For those at the forefront of oncology innovation, World ADC Asia 2024 is an unmissable opportunity to witness the field exhilarating advancements fuelled by clinical progress and strategic collaborations. [Secure your spot today](#) and take advantage of early registration and group discounts.

For more information about World ADC Asia please visit: www.worldadc-asia.com

About the Organizer:

Backed by almost 15 years of experience providing insights to the global community, World ADC is the perfect opportunity to gain unbiased insights and meet the pioneers in the space who are propelling innovation in the region and accelerating antibody-drug conjugates to approval.

World ADC is part of Hanson Wade Limited Group. Based in the UK, Hanson Wade Conferences improve drug development decision-making to accelerate safer, more effective, and accessible drugs to patients in need. We provide biopharmaceutical leaders unrivalled access to premium content and insight. Critical information, delivered by world-class industry speakers to progress the right targeted therapies to the right patients, faster.

For More Information please contact:

Jessica Durston

Marketing Manager – World ADC Team Hanson Wade

adc@hansonwade.com